On April 1, 2026, the FDA approved Foundayo (orforglipron), and the weight-loss landscape changed overnight. It’s the first oral small-molecule GLP-1 receptor agonist ever approved — a genuinely different kind of drug from every GLP-1 that came before it, pill or injection. It was also approved in record time, clearing FDA review in just 50 days as the first drug ever authorized under the agency’s Commissioner’s National Priority Voucher (CNPV) pilot program.
This guide covers everything currently known about Foundayo: what makes its chemistry unique, what the pivotal ATTAIN-1 trial showed, what it costs, and how to actually get a prescription. As your complete GLP-1 resource — injections and pills alike — WeightLossInjections.com is tracking Foundayo closely as it becomes one of the most searched weight-loss drugs of 2026.
Key Takeaways
- Foundayo (orforglipron) is Eli Lilly’s first-in-class oral small-molecule GLP-1 receptor agonist, approved April 1, 2026, for chronic weight management.
- It was approved in 50 days under the FDA’s Commissioner’s National Priority Voucher program — the first drug cleared through that pathway.
- Unlike every other oral GLP-1, Foundayo requires no fasting, no water restrictions, and no specific time of day — take it whenever fits your routine.
- In the pivotal ATTAIN-1 trial, participants lost 14.7-16.9% of body weight at 52 weeks, dose-dependently.
- Pricing ranges from $25/month with commercial insurance and a savings card to $149-349/month self-pay, with a $50/month Medicare option starting July 1, 2026.
- Foundayo is not yet approved for type 2 diabetes; that filing is expected later in 2026 based on the ACHIEVE program.
What Is Foundayo (Orforglipron)?
Foundayo is the brand name for orforglipron, developed by Eli Lilly under the research code LY3502970. It belongs to a new category: the first-in-class oral, non-peptide, small-molecule GLP-1 receptor agonist. Every other GLP-1 drug on the market — whether an injectable like Ozempic, Wegovy, Mounjaro, or Zepbound, or an oral peptide like Rybelsus or the Wegovy pill — is built around a large peptide molecule that mimics the natural GLP-1 hormone. Orforglipron is structurally nothing like those. It’s a small molecule, chemically closer to a conventional tablet drug, that still activates the GLP-1 receptor.
Foundayo is FDA-approved for chronic weight management in adults with obesity (BMI ≥30) or who are overweight (BMI ≥27) with at least one weight-related comorbidity, such as high blood pressure, type 2 diabetes, or high cholesterol. It is not currently approved for type 2 diabetes as a standalone indication — Eli Lilly’s ACHIEVE clinical program (ACHIEVE-1 through ACHIEVE-4) is generating the data expected to support a future diabetes-specific application, according to Eli Lilly’s press materials.
The FDA Approval: A Record-Setting 50 Days
Foundayo’s approval is notable not just for what the drug is, but for how fast it got to market. Eli Lilly’s New Drug Application was reviewed and approved in roughly 50 days — described as the fastest approval of a new molecular entity since 2002. That speed was possible because Foundayo was the first drug ever approved under the FDA Commissioner’s National Priority Voucher (CNPV) program, a pilot designed to accelerate review of medicines addressing significant public health needs. Eli Lilly’s April 2026 press release detailed the approval, and the FDA’s own Drugs@FDA database confirms the April 1, 2026 clearance date.
Why Foundayo Is Different: The Small-Molecule Advantage
Every peptide-based GLP-1 — injectable or oral — faces the same biological problem: peptides are fragile. They break down quickly in the digestive tract, which is why injectable versions bypass the gut entirely, and why oral peptide versions like Rybelsus and the Wegovy pill need a special absorption enhancer (SNAC) plus strict fasting rules to get enough drug into the bloodstream.
Orforglipron avoids that problem altogether because it isn’t a peptide. As a small molecule, it survives passage through the stomach and intestines without needing protection, and food doesn’t interfere with its absorption the way it does with peptide-based oral drugs. That’s the reason Foundayo can be taken once daily, at any time, with or without food or water — a first for any GLP-1 medication.
The trade-off is efficacy: small-molecule GLP-1 agonism appears to produce somewhat lower peak weight loss than the larger peptide-based drugs. ATTAIN-1 data put Foundayo in the 14.7-16.9% range at 52 weeks, compared with roughly 16.6% for the Wegovy pill (OASIS 4) and around 22.5% for the dual-acting injectable Zepbound. Some FDA label analyses reference an 11.2% figure over a longer 72-week window, reflecting different dosing arms and time points.
Our Top 3 · July 2026
The best GLP-1 providers right now
Independently reviewed. Ranked by price, medication access, provider quality, and patient outcomes.
Renew GLP
Personalized GLP-1, GIP plans: Semaglutide & Tirzepatide.
Medvi
No membership or hidden fees. Everything you need is included.
Trimi
US-licensed clinicians and shipped to your door, from $99/mo.
ATTAIN-1: The Pivotal Trial Behind the Data
ATTAIN-1 (ClinicalTrials.gov NCT05674877) was the Phase 3 trial that supported Foundayo’s weight-loss approval. In it, participants with obesity or overweight plus a weight-related comorbidity were randomized to different doses of orforglipron or placebo. At 52 weeks, weight loss was dose-dependent, landing in the 14.7-16.9% range for the higher doses, versus roughly 2.3% for placebo. A companion trial, ATTAIN-2, examined orforglipron in people with both obesity and type 2 diabetes and produced supporting data used in the FDA submission.
Separately, the ACHIEVE program is testing orforglipron specifically for type 2 diabetes. ACHIEVE-4, a head-to-head study against insulin glargine in more than 2,700 participants with type 2 diabetes, obesity, and cardiovascular risk, reported topline results on April 16, 2026 — expected to support a future diabetes indication filing.
Foundayo vs. Other Oral GLP-1s
| Feature | Foundayo (orforglipron) | Wegovy pill | Rybelsus |
|---|---|---|---|
| Molecule type | Small-molecule (non-peptide) | Peptide (semaglutide) | Peptide (semaglutide) |
| Approved for weight loss? | Yes | Yes | No (off-label only) |
| Fasting required? | No | Yes (strict, 30 min) | Yes (strict, 30 min) |
| Water restriction | None | ≤4 oz | ≤4 oz |
| Weight loss (trial) | 14.7-16.9% (ATTAIN-1) | ~16.6% (OASIS 4) | ~4-6 lbs (secondary endpoint) |
| Self-pay price range | $149-349/month | ~$1,349/month list | ~$1,000/month list |
Foundayo Pricing
Foundayo’s price varies significantly depending on your insurance and pharmacy channel:
- Commercial insurance with a manufacturer savings card: as low as $25/month
- Self-pay (no insurance): $149-349/month depending on dose
- Medicare Part D: $50/month through the Medicare GLP-1 Bridge program, available starting July 1, 2026
For a full breakdown of oral GLP-1 pricing across all three approved drugs, see our oral GLP-1 cost guide.
How to Get Foundayo
Foundayo is available through several channels:
- LillyDirect — Eli Lilly’s direct-to-consumer platform for ordering and home delivery
- GoodRx — self-pay pricing around $149/month through participating pharmacies
- Retail pharmacies — CVS, Walgreens, Walmart, Kroger, and Amazon Pharmacy all carry Foundayo with a valid prescription
- Telehealth providers — services like Ro, Hims & Hers, LifeMD, and Mochi can facilitate prescriptions following a clinical evaluation
A prescription requires an evaluation by a licensed healthcare provider to confirm you meet the BMI and comorbidity criteria for the weight-loss indication.
Safety Considerations
Foundayo shares the class-wide GLP-1 side effect profile: nausea, vomiting, diarrhea, constipation, and reduced appetite, most pronounced during dose titration. ATTAIN-1 data also noted transaminase (liver enzyme) elevations in some participants, which is why routine monitoring may be recommended. Like all GLP-1 receptor agonists, Foundayo carries a boxed warning regarding the risk of thyroid C-cell tumors and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome. Foundayo may also require dose adjustments with certain CYP3A4-affecting drugs, and effectiveness of oral contraceptives may be reduced during titration — discuss any medication interactions with your prescriber.
FAQ
Is Foundayo the same as orforglipron?
Yes. Foundayo is the FDA-approved brand name for orforglipron, Eli Lilly’s oral small-molecule GLP-1 receptor agonist.
Do I need to fast before taking Foundayo?
No. Foundayo is the only oral GLP-1 that doesn’t require fasting or water restrictions — it can be taken any time of day, with or without food or water.
How much weight can you lose on Foundayo?
In the ATTAIN-1 trial, participants lost an average of 14.7-16.9% of body weight at 52 weeks, depending on dose, compared to about 2.3% with placebo. Individual results vary.
Is Foundayo covered by insurance?
Coverage varies by plan. Many commercial insurance plans cover Foundayo with a savings card that can bring the cost to as low as $25/month, and a Medicare Part D pathway offering $50/month coverage begins July 1, 2026.
Is Foundayo approved for type 2 diabetes?
Not yet. As of mid-2026, Foundayo is approved only for chronic weight management. A separate application for type 2 diabetes is expected later in 2026, supported by the ACHIEVE clinical trial program.
Medical disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Foundayo (orforglipron), Wegovy pill (oral semaglutide 25 mg), and Rybelsus (oral semaglutide 3/7/14 mg) are prescription medications with important safety information and contraindications. Discuss any medication decision with a qualified healthcare provider. Content published by WeightLossInjections.com, your complete resource for GLP-1 medications — injections and pills alike.
